BioStock published an article on 20 December 2021 about Cyxone, which can be read in full below. In the preparation for the coming phase IIb trial with Rabeximod in rheumatoid arthritis, biotech company Cyxone has entered an Early Operations...
Read MoreBioStock published an article on 8 November 2021 about Cyxone, which can be read in full below. Biotech company Cyxone is developing T20K, a drug candidate with first-in-class potential for the treatment of multiple sclerosis. Recently, Cyxone’s research partner,...
Read MoreIt is time for 2021’s edition of the largest partnering meeting in the life science space – BIO-Europe. This week, representatives from nearly 1,500 companies will gather to establish new contacts as well as continue initiated discussions with potential...
Read MoreBioStock published an article on 16 August 2021 about Cyxone, which can be read in full below. Swedish biotech Cyxone announced last month that the patient recruitment for its phase II trial testing Rabeximod in Covid-19 could come to...
Read MoreBioStock published an article on 15 July 2021 about Cyxone, which can be read in full below. After identifying new therapeutic treatment possibilities for T20K, Cyxone has announced a research collaboration with the Medical University of Vienna to further...
Read MoreBioStock published an article on 14 June 2021 about Cyxone, which can be read in full below. During May, Swedish biotech company Cyxone released a string of news. Recently, the company announced the recruitment of Carl-Magnus Högerkorp as new...
Read MoreBioStock published an article on 28 May 2021 about Cyxone, which can be read in full below. World MS Day will be celebrated on Sunday May 30th. It is a day to raise awareness of the condition, and to...
Read MoreBioStock published an article on 20 May 2021 about Cyxone, which can be read in full below. Recently, Malmö-based company Cyxone, announced the next development steps for its drug candidate T20K for the treatment of multiple sclerosis. A process...
Read MoreBioStock published an article on 18 May 2021 about Cyxone, which can be read in full below. Biotech company Cyxone is in the process of preparing drug candidate Rabeximod for the next clinical stage. Recently, the company announced a...
Read MoreRead the article with CEO Tara Heitner and COO Malin Berthold telling the story how Cyxone initiated the Covid-19 trial. Read the article here.
Read More